Aptabio Therapeutics압타바이오
293780 · KOSDAQ · ₩293780 · 압타바이오
₩5,090▼ ₩220 (4.14%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 48.1% | 36.0% | 8.5% | 24.2% | — | — |
| Operating margin | −394.4% | −428.4% | −561.0% | −5,055.6% | −19,661.2% | −5,081.9% |
| Net margin | −312.8% | −442.0% | −874.1% | −3,724.2% | −21,849.3% | −4,778.8% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +28.5% | +10.0% | +937.8% | +569.8% | −78.4% | — |
| Operating income growth | −18.3% | +16.0% | −15.2% | −72.2% | +16.4% | — |
| Net income growth | +9.0% | +44.4% | −143.6% | −14.2% | +1.2% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −33.3% | −32.2% | −50.8% | −21.2% | −18.5% | −17.3% |
| Return on assets | −26.0% | −23.8% | −34.6% | −16.2% | −17.5% | −16.5% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 28.9% | 27.2% | 42.9% | 50.8% | 7.1% | 5.3% |
| Net debt to equity | −19.6% | −20.8% | −28.5% | −22.8% | — | — |
| Current ratio | 253.8% | 260.9% | 178.8% | 7,026.6% | 1,963.3% | 3,019.0% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Aptabio Therapeutics / 압타바이오 / 293780 / KRX:293780
Source: KRX statistical information